OptimizeRx Corp. (NASDAQ:OPRX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of OptimizeRx Corp. (NASDAQ:OPRX) have been given an average rating of “Moderate Buy” by the nine analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $11.4286.

A number of equities analysts recently commented on OPRX shares. Citigroup restated a “market outperform” rating on shares of OptimizeRx in a report on Friday, August 14th. B. Riley Financial cut their price target on shares of OptimizeRx from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Stifel Nicolaus set a $12.00 price objective on shares of OptimizeRx in a research note on Thursday, August 13th. Stephens lowered their target price on shares of OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 13th. Finally, Lake Street Capital cut their target price on OptimizeRx from $20.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th.

Institutional Investors Weigh In On OptimizeRx

Institutional investors have recently bought and sold shares of the business. Quantbot Technologies LP acquired a new position in shares of OptimizeRx in the 2nd quarter valued at $44,000. BNP Paribas Financial Markets grew its stake in shares of OptimizeRx by 119.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after purchasing an additional 2,215 shares during the period. Aaron Wealth Advisors LLC bought a new stake in shares of OptimizeRx in the 1st quarter valued at approximately $66,000. Worth Venture Partners LLC acquired a new position in shares of OptimizeRx in the 3rd quarter worth approximately $220,000. Finally, ExodusPoint Capital Management LP acquired a new position in shares of OptimizeRx in the 4th quarter worth approximately $150,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Price Performance

Shares of NASDAQ:OPRX opened at $7.86 on Wednesday. The firm has a market cap of $148.08 million, a price-to-earnings ratio of 34.18 and a beta of 1.08. OptimizeRx has a 1 year low of $4.54 and a 1 year high of $22.25. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 0.14. The business has a fifty day simple moving average of $6.50 and a 200 day simple moving average of $6.55.

OptimizeRx (NASDAQ:OPRX) last issued its earnings results on Wednesday, August 12th. The company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05. OptimizeRx had a return on equity of 9.44% and a net margin of 4.66%.The firm had revenue of $20.50 million for the quarter, compared to the consensus estimate of $20.20 million. As a group, sell-side analysts predict that OptimizeRx will post 0.51 earnings per share for the current fiscal year.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.